EU/3/14/1401: Orphan designation for the treatment of traumatic spinal cord injury

Riluzole

Overview

On 16 December 2014, orphan designation (EU/3/14/1401) was granted by the European Commission to Dr Laurent Vinay, France, for riluzole for the treatment of traumatic spinal cord injury.

Key facts

Active substance
Riluzole
Intended use
Treatment of traumatic spinal cord injury
Orphan designation status
Positive
EU designation number
EU/3/14/1401
Date of designation
16/12/2014
Sponsor
Dr Laurent Vinay
Institut des Neurosciences de la Timone
Campus Santé Timone
27 bd Jean Moulin
13385 Marseille cedex 05
France
Tel. +33 4 91 32 40 51
Fax +33 4 91 32 40 56
E-mail: laurent.vinay@univ-amu.fr

Review of designation

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating